Recent Advances in the Pharmacology of Spinocerebellar Ataxia
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 2153
Special Issue Editors
Interests: gene therapy; polyglutamine diseases; ataxin-2; ataxin-3; neurodegeneration; stress granules
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Spinocerebellar ataxias (SCAs) comprise a group of neurodegenerative diseases, now including more than 40 different pathologies. While heterogeneous in terms of cause, disease characteristics, and even progression, they are all characterized by a main degeneration of the cerebellum, which is accompanied by degenerative alterations in other regions of the nervous system. This cerebellar degeneration translates into a loss of coordination, particularly gait, being this ataxia the most prominent symptom of SCA patients. While individually most of these diseases are rare, as a group they have an important dimension and are a current focus of research. Importantly, all the treatments available are symptomatic, as there is no disease modifying therapy that could stop or delay the disease progression. Therefore, there is an urgent need for new treatments for these incurable diseases.
In this line, this special issue aims to provide an updated view on the advances made in the development of drugs aiming to treat spinocerebellar ataxias, focusing both on new drugs being used in patients both in clinics and in clinical trials, but also providing an updated view on the promising drugs that are being studied in a preclinical setting.
Dr. Clévio Nóbrega
Prof. Dr. Laura Bannach Jardim
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- spinocerebellar ataxias
- ataxia
- pharmacology
- drugs
- therapies
- neurodegeneration
